DiaSorin stock

DIA · Borsa Italiana · EUR

Compare DiaSorin
€77.84Change from previous close: −1.99%Absolute change: −€1.58

Close · November 20, 2026

Price history

+32.38% over the period

1 year: from €58.80 (November 20, 2025) to €77.84 (November 20, 2026), +32.38%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 20, 2026€77.84
October 30, 2026€80.56
September 30, 2026€76.80
August 31, 2026€75.88
July 31, 2026€71.86
June 30, 2026€67.76
May 29, 2026€66.52
April 30, 2026€58.02
March 31, 2026€59.98
February 27, 2026€71.20
January 30, 2026€72.18
December 30, 2025€68.62
November 28, 2025€61.78
November 20, 2025€58.80

At a glance

  • The company

    Develop, manufacture and distribute immunodiagnostic and molecular diagnostic testing kits for infectious diseases, endocrinology, oncology and other medical areas

  • Latest results

    Quarter to June 30, 2026 · EPS €1.04 (estimate €1.00)

TickerLandia's take on DiaSorin

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low€52.34
52-wk high€85.82

−9.30% from the 52-week high

Analysts · 14 analysts

Average target€80.14+2.96% vs. price

Buy 5 · Hold 4 · Sell 5 · Hold

TickerLandia Fingerprint: DiaSorin

Compared with similar companies: very strong momentum.

Financials and price compared with 27 companies in the diagnostics & research industry, worldwide. Momentum and risk compared with 1,160 European stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

DiaSorin is priced as in the past and in line with similar companies

On the latest fiscal year's earnings (2025), DiaSorin's P/E today is 27.3, in line with the median of its last 10 fiscal years (30.3; between 24.1 and 37.8 from 2016 to 2025). DiaSorin's P/E (trailing 12 months): 28.6, in line with the median of a group of 11 similar companies (28.6).

P/E compared with its history

Compared with 11 similar companies

DiaSorin's metrics compared with similar companies
MetricDiaSorinPosition in the groupBand
P/E (trailing 12 months)28.6Middle
Forward P/E17.9Middle
Operating margin22.3%Middle
ROE9.2%Middle
Debt/equity0.53Middle

P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: DiaSorin. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

€314.62M

Latest quarter · Q2 2026

Net income

€46.35M

Latest quarter · Q2 2026

Quarterly net margin

14.7%

Latest quarter · Q2 2026

Numbers and valuation

Full valuation
Market cap
€3.83B
P/E
28.6
EPS
€2.72
Volume
114.94K
Daily trading
€11.01M
Dividend yield
1.67%
Last ex-dividend on May 18, 2026

How DiaSorin is changing

All results
  • Revenue grew 6.3% a year on average over the last 5 years

  • Operating margin fell from 27.5% to 23.0%

  • Profits turn into cash: free cash flow equal to 170% of net income

Returns

DiaSorin returns with dividends

€1,000 invested in DiaSorin 5 years ago, on November 22, 2021, would be worth €451 today with dividends reinvested: −54.90% in total, −14.74% per year. On price alone it would be €424 (−57.62%).

PeriodDiaSorinFTSE MIB€1,000 becomes
1 month−2.09%−0.75%€979
6 months+14.88%−0.97%€1,149
Year to date+13.44%+8.36%€1,134
1 year+34.82%+13.48%€1,348
3 years−8.21%+64.86%€918
5 years−54.90%+77.86%€451
10 years+71.38%+198.85%€1,714

Over the last 6 months it has done better than 47% of the stocks in the Healthcare sector.

From 1 year up with dividends reinvested, before taxes; under a year price only. FTSE MIB: price only. Calculate your investment

The chart in detail

DiaSorin: technical analysis

DiaSorin shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 62.8% below its all-time closing high (€209.40, May 25, 2020).

Trend
No clear trend
RSI (14 sessions)
41
Between 30 and 70
vs 200-session average
+10.05%

Active signals

  • Close below the low of the previous 20 sessions.

Support and resistance

Price areas where DiaSorin has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistance€79.45+2.07%3 touches, last on November 6, 2026
  2. Last price€77.84
  3. Support€77.57−0.35%2 touches, last on August 28, 2026
  4. Support€76.18−2.13%5 touches, last on October 19, 2026
  5. Support€72.37−7.03%5 touches, last on October 2, 2026

Volatility and risk

Over the last year it has moved little with the FTSE MIB.

Beta (1 year) vs FTSE MIB
0.22
Volatility (60 sessions, annualised)
23.9%
Largest fall in the last year
−26.80%

Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

DiaSorin: seasonality

Average monthly price change over 20 years

+0.8%Jan+0.2%Feb−0.6%Mar+1.8%Apr+4.9%May+1.9%Jun+2.9%Jul+1.0%Aug−1.0%Sep+1.8%Oct−0.3%Nov+0.2%Dec

Over the last 20 years, the strongest month for DiaSorin has been May: +4.90% on average, positive in 16 years out of 19. The weakest has been September: −1.01% on average, positive in 8 years out of 20. November, the current month, has been positive in 8 years out of 19 (−0.29% on average).

Show chart data
MonthAverageMedianPositive years
January+0.75%+0.10%10 of 19
February+0.16%−1.36%9 of 19
March−0.57%−0.68%8 of 19
April+1.76%+0.93%12 of 19
May+4.90%+4.85%16 of 19
June+1.89%−0.55%8 of 19
July+2.88%+3.23%13 of 19
August+1.04%+1.14%12 of 20
September−1.01%−1.13%8 of 20
October+1.83%+3.64%12 of 20
November−0.29%−2.17%8 of 19
December+0.21%−0.39%9 of 19

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

DiaSorin and its competitors

With 3,212 employees and sales of 1.2 billion euros in the fiscal year ended December 2025, the company develops, makes and distributes diagnostic test kits for clinical laboratories. Its immunoassay menu covers infections, digestive disorders, hepatitis and retroviruses, hormones, metabolic conditions and tumor markers, run on its LIAISON instruments. Its molecular line includes a congenital cytomegalovirus kit that detects viral DNA in saliva and urine, a respiratory panel, a yeast blood culture assay and the xMAP multiplexing platform. Products are sold in Europe, North America and other international markets.

Headquarters
Saluggia, Italy
Employees
3,212
Founded
1968
Chief executive
Carlo Rosa
DiaSorin and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
DiaSorinDIA$4.21B22.3%28.6+14.88%
QiagenQIA$10.23B26.7%28.5+50.69%
bioMérieuxBIM$11.82B16.0%23.4+25.67%
DiagnostykaDIA$1.27B14.9%20.2−6.62%
Eurofins ScientificERF$16.03B14.1%29.6+37.31%
Lonza GroupLONN$54.2B23.5%43.2+32.22%

Same industry or related industries, similar size. Compare DiaSorin with its competitors · Full profile